Akamai Technologies Free cash flow decreased by 10.2% to $210.82M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 58.0%, from $133.42M to $210.82M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -1.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $270.90M | $319.06M | $323.06M | $171.45M | $267.22M | $318.50M | $276.25M | $91.80M | $254.01M | $225.94M | $318.79M | $258.13M | $339.97M | $279.74M | $250.90M | $133.42M | $313.61M | $329.05M | $234.89M | $210.82M |
| QoQ Change | — | +17.8% | +1.3% | -46.9% | +55.9% | +19.2% | -13.3% | -66.8% | +176.7% | -11.1% | +41.1% | -19.0% | +31.7% | -17.7% | -10.3% | -46.8% | +135.0% | +4.9% | -28.6% | -10.2% |
| YoY Change | — | — | — | — | -1.4% | -0.2% | -14.5% | -46.5% | -4.9% | -29.1% | +15.4% | +181.2% | +33.8% | +23.8% | -21.3% | -48.3% | -7.8% | +17.6% | -6.4% | +58.0% |